SynthesisFrontiers in immunology2026
Critical analysis of pemphigus vulgaris in pregnancy.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human pregnancy is a complex, interesting and challenging interplay between the hormonal and immune systems. The presence of an autoimmune disease adds to this complexity. Presence of pemphigus vulgaris (PV) in a pregnant patient should be considered a "high risk pregnancy", by all health care providers involved, from implantation to post-partum care and thereafter. In this systemic review, data from 90 studies involving 111 pemphigus vulgaris patients who were pregnant has been critically analyzed. Patients who had PV before pregnancy and those who developed it during pregnancy were studied and outcomes were compared and are discussed. Systemic corticosteroids (CS) remain the mainstay of treatment. The role of the placenta in producing endogenous cortisol should be considered in adjusting these doses during the last trimester and post-partum. The data in this analysis clearly demonstrates that the clinical and serological control of and the remission of PV is one of the most important factors that influences and predicts maternal health, gestational complications, post-partum exacerbations, neonatal pemphigus and fetal mortality. Observations from this comprehensive review indicate that PV does not preclude successful pregnancy. Critical outcomes measured are probably similar in women who have PV before pregnancy or develop it during pregnancy. The incidence of neonatal pemphigus was 38%, fetal mortality was 9.8% and post-partum flares occurred in 37% of patients. These observations correlated with lack of control of maternal disease during pregnancy. Frequent maternal and fetal monitoring should be considered. Topical therapy should be encouraged since it may decrease the need for higher doses of CS. Azathioprine appears to be the safest immunosuppressive agent in these patients. When available and affordable intravenous immunoglobulin (IVIg) can provide significant benefits. Mucocutaneous disease had more significant consequences than only cutaneous disease. However 70-80% of the patients had oral disease. Therefore oral health care providers should be aware of pemphigus in pregnancy. In some patients, PV may persist after pregnancy, especially if it was present and active post-partum. Patients with PV in a child-bearing age should be advised to get pregnant when PV is in remission. Optimal outcome requires team-work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.